{"disease":{"id":"adjuvant-treatment-of-stage-iii-colon-cancer","name":"adjuvant treatment of stage iii colon cancer"},"drugs":{"marketed":[{"drug_id":"capecitabine","indication_name":"Adjuvant treatment of Stage III colon cancer","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Xeloda","generic_name":"capecitabine","company_name":"Cheplapharm","drug_phase":"marketed","molecular_target":"Thymidylate synthase","drug_class":"Nucleoside Metabolic Inhibitor [EPC]","quality_score":67,"revenue":null,"mechanism":"Xeloda works by inhibiting the enzyme thymidylate synthase, which is necessary for DNA synthesis in cancer cells."}],"pipeline":[],"offLabel":[],"totalMarketed":1,"totalPipeline":0},"trials":{"data":[],"total":0},"guidelines":[{"drug_id":"capecitabine","guideline_body":"FDA label","recommendation":"Capecitabine is indicated for adjuvant treatment of patients with Stage III colon cancer as a single agent or as a component of a combination chemotherapy regimen.","line_of_therapy":"adjuvant","evidence_grade":"not specified","guideline_year":null}],"source":"Drug Landscape verified database"}